Next Article in Journal
Redox State of Human Serum Albumin in Multiple Sclerosis: A Pilot Study
Next Article in Special Issue
Emerging Roles of Endocannabinoids as Key Lipid Mediators for a Successful Pregnancy
Previous Article in Journal
The New General Biological Property of Stem-like Tumor Cells (Part II: Surface Molecules, Which Belongs to Distinctive Groups with Particular Functions, Form a Unique Pattern Characteristic of a Certain Type of Tumor Stem-like Cells)
Previous Article in Special Issue
Fat Checking: Emerging Role of Lipids in Metabolism and Disease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 24
10.3390/ijms232415809
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Mechanism Underlying Naringenin Hypocholesterolemic Effects: Involvement of Estrogen Receptor α Subtype

by
Valentina Pallottini
1,2,*,†,
Marco Segatto
3,†,
Filippo Acconcia
1,
Marco Fiocchetti
1,2 and
Maria Marino
1,2
1
Department of Science, Section Biomedical Science and Technology, University Roma Tre, Viale Marconi 446, 00146 Rome, Italy
2
Neuroendocrinology Metabolism and Neuropharmacology Unit, IRCSS Fondazione Santa Lucia, Via del Fosso Fiorano 64, 00143 Rome, Italy
3
Department of Biosciences and Territory, University of Molise, Contrada Fonte Lappone, 86090 Pesche, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Mol. Sci. 2022, 23(24), 15809; https://doi.org/10.3390/ijms232415809
Submission received: 21 November 2022 / Revised: 8 December 2022 / Accepted: 10 December 2022 / Published: 13 December 2022
(This article belongs to the Special Issue Emerging Role of Lipids in Metabolism and Disease – 3rd Edition)
Browse Figures
Review Reports Versions Notes

Abstract

:
Naringenin (Nar) is one of major citrus flavonoids predominantly found in grapefruit and orange. In vivo studies have demonstrated Nar potential as a normolipidemic agent capable to reduce circulating cholesterol in hypercholesterolemic rabbits, rats, and patients, suggesting a new role for this molecule in cardiovascular disease prevention. Although Nar cholesterol-lowering effects are known, the underlying mechanisms have not yet been elucidated. Interestingly, Nar binds to the estrogen receptors (ERs), modulating both transcriptional and membrane-initiating signals. Although estrogen and ERs are deeply involved in lipid metabolism, no data are available regarding a putative role of these nuclear receptors as mediators of the hypocholesterolemic effect exerted by Nar. Thus, the aim of this work was to study the involvement of ERs in Nar-induced modulation of cholesterol metabolism. Results obtained in HepG2 cell line demonstrate that Nar can modulate the molecular network of cholesterol homeostasis. However, these effects were only partially dependent on the activity of estrogen receptor α. As a whole, our data highlight new molecular mechanisms by which Nar influences cholesterol metabolism, opening a new scenery about dietary impact on human health.

1. Introduction

Coronary heart disease (CHD) is the major cause of morbidity and mortality in Western industrialized countries. Every year, cardiovascular disease (CVD) kills approximately 16 million people. In the US, 43% of deaths are attributable to CVD, and in 2019, an estimated 558,000 deaths were caused by coronary heart disease, and 109,000 deaths were caused by ischemic stroke [1].
A positive correlation among elevated blood levels of low-density lipoprotein cholesterol (LDL-C), atherosclerosis, and coronary heart disease has been assessed; therefore, dyslipidemia is one of the main risk factors leading to CHD. Prevention of CHD remains a goal for researchers working with health or pharmaceutical care. In primary prevention, several modifiable risk factors should be considered for controlling this disease, such as the combination of smoking, hypertension, hyperlipidemia, obesity, sedentary life, and dyslipidemia. However, it is quite difficult to control cholesterol levels and meet the aggressive targets for plasma LDL-C concentrations by modifying daily habits alone. Thus, pharmacological intervention is often necessary. Three main classes of compounds are used in current clinical practice to treat dyslipidemia: statins, a primary therapeutic tool, fibrates, monoclonal antibodies, synthetic interfering RNA (siRNA), and bile-acid sequestrants or resins [2,3]. Because of the seriousness of the illness, the potentially huge patient population, and the several side effects of current medications [4,5], discovery and development of new cholesterol lowering agents with different sites or action mechanisms from those of existing drugs are demanding for researchers both in academia and industry.
It has been recognized that a high intake of fruits and vegetables protects against chronic diseases. Among fruits and vegetables, the protective relationship between the consumption of citrus fruits or juices and the risk of ischemic stroke has been demonstrated [6]. In addition, it has been reported that high consumption of citrus juice or grapefruit improved blood lipid profile in hyperlipidemic humans [7]. Citrus juices, especially orange juice and grapefruit juice are rich source of flavonoids: naringenin (Nar) being the main component. In liver-derived human cell lines (i.e., HepG2 cells), Nar was shown to reduce the secretion of very low-density lipoprotein (VLDL) [8,9] through the inhibition of acyl-coenzyme A:cholesterol acylTransferase (ACAT2) [8] and microsomal triglyceride transfer protein (MTP) [10,11], enzymes critical for VLDL assembly. Nar was also shown to induce LDL receptor transcription through phosphatidyl inositol 3 kinase (PI3K) activation upstream of sterol regulatory element-binding protein 1a (SREBP-1a), a transcription factor involved in lipid metabolism [8,11]. Other studies demonstrated that Nar activated enzymes important in fatty acid oxidation such as CYP4A1, whereas the same compound inhibited hydroxy methyl-glutaryl coenzyme A reductase (HMGCR), the key and rate-limiting enzyme of cholesterol biosynthetic pathway [12]. Interestingly, the Nar hypocholesterolemic effects may be determined by the direct HMGCR inhibition. Indeed, in vitro it has been shown that at millimolar doses, Nar directly interacts with HMGCR catalytic site with affinities similar to those observed for statins [13]. However, the precise molecular mechanisms underlying Nar effects are not fully elucidated. In addition to the ability of high Nar concentrations to interact with enzymes, the flavanone biological effects have been ascribed to different molecular mechanisms, which include the binding to the estrogen receptors (ERs) [14]. Epidemiologic studies have shown that prior to menopause, women are at a lower risk of developing CVD compared to men. Women also have decreased CVD-associated morbidity compared to age-matched men and develop CVD 10 years later than men [15]. Experiments on animal models have demonstrated that these cardioprotective effects of pre-menopausal status are mainly conferred by the action of circulating estrogen on the α subtype of the ERs (ERα). Loss of ERα increased the occurrence of atherosclerotic lesions through elevated serum cholesterol levels and increased high-density lipoprotein particle size [16]. Estrogen/ERα complex decreases blood pressure, promotes vasodilation, and reduces the proliferation and migration of vascular smooth muscle cells (VSMCs) [17,18]. Our previous studies demonstrated that Nar, at concentrations compatible with that present in the blood after a meal enriched with flavonoids, impaired ERα rapid signaling by interfering with ERα-mediated activation of ERK and PI3K pathways without any effects on the receptor transcriptional activities [14,19,20]. Estrogen receptors (ERs) are deeply involved in lipid metabolism [20,21,22,23], but there is no evidence regarding a putative role of these nuclear receptors as mediators of the hypocholesterolemic effect exerted by Nar. Thus, this work aims at studying the involvement of ERα in Nar-induced modulation of protein network implicated in cholesterol homeostasis. For this purpose, HepG2 cells, which express only ERα subtype [24,25], have been chosen as a well-established experimental model to study lipid metabolism. Notably, this cells line retains several human liver functions, including lipid synthesis and secretion of albumin, apoB, and lipoproteins in response to various nutritional or physiological stimulations [26,27].

2. Results

Nar effects on the main proteins committed to cholesterol homeostasis were assessed by studying the level of HMGCR, the key and rate-limiting enzyme of cholesterol biosynthetic pathway, that catalyzes the first committed step in cholesterol biosynthesis. HMGCR phosphorylation, which represents the enzyme short-term inhibition [28], and the expression of low-density lipoprotein receptor (LDLR) were also evaluated in cells treated with Nar. Twenty-four hours after Nar treatment, the HMGCR expression showed a dose-dependent reduction, whereas its phosphorylation state increased (Figure 1A), suggesting a reduction of intracellular cholesterol synthesis. On the other hand, already at 10−7 M, Nar induces the increase of LDLR, which is suggestive of an enhanced LDL cholesterol uptake (Figure 1B).
The increased HMGCR phosphorylation state mediated by Nar prompted us to evaluate the proteins involved in the enzyme short-term regulation, and we selected 10−6 M Nar concentration since at this dose we already obtained the maximum effect on HMGCR. Thus, the level of phosphorylation (i.e., activation) of AMP-activated kinase (AMPK), the major HMGCR kinase at least in the liver, and the level of protein phosphatase 2A (PP2A) catalytic subunit, which activates HMGCR by de-phosphorylation [29,30], have been assessed. Nar stimulation (10−6 M for 24 h) increases AMPK phosphorylation state (Figure 2A) and, concurrently, it significantly reduces the levels of PP2A catalytic sub-unit (Figure 2B).
These results prompted us to evaluate if Nar could also affect the key proteins controlling HMGCR and LDLR long-term regulation. Long-term regulation acts through transcriptional, translational, and post-translational control [31]. SREBP cleavage activating protein (Scap), an escort protein for SREBPs embedded in the endoplasmic reticulum [32], binds to SREBPs and escorts them from the ER to the Golgi apparatus where SREBPs are proteolytically processed to yield N-terminal active fragments (nSREBPs), which enter the nucleus and induce the expression of their target genes [28], in sterol-deprived cells. When cholesterol builds up in endoplasmic reticulum membranes, the migration of the Scap/SREBP complex is blocked, the proteolytic processing of SREBPs is abolished, and the transcription of the target genes declines. Endoplasmic reticulum retention of Scap/SREBP is mediated by sterol-dependent binding of Scap/SREBP to the endoplasmic reticulum resident Insig (INSulin Induced Gene) proteins [31]. Moreover, intracellular accumulation of sterols triggers binding of HMGCR to Insigs, which, in turn, initiate the ubiquitination and the subsequent proteasomal degradation of the enzyme [33].
Figure 3A shows that Nar treatment suppressed the production of the transcriptionally active fragment of SREBP-1, whereas no changes were observed in SREBP-2 (Figure 3A) or in Scap (Figure 3B). Furthermore, Nar administration also increased the expression of both Insig-1 and -2 proteins (Figure 3C). Taken together, these data suggest that Nar is not only able to modulate cholesterol metabolism by affecting the SREBP-1-dependent transcriptional regulation of genes committed to cholesterol metabolism, but it is also able to reduce HMGCR levels through Insig-dependent enzyme degradation [33].
The reduction of SREBP-1 mediated by Nar, together with the increase of Insig proteins, strongly corroborates the HMGCR decrease. Conversely, the LDLR increase cannot be explained by the observed variations of these regulatory proteins. Therefore, we checked the level of the proprotein convertase subtilisin kexin 9 (PCSK9), a 72-kDa protease highly expressed in the liver under the control of SREBPs. Once secreted, PCSK9 binds LDLR, inducing the redistribution of the receptor from the cell surface to lysosomes; indeed, PCSK9 appears to change the trafficking of the LDLR, diverting the internalized LDLR to degradation in lysosomes and preventing them from being recycled to the cell surface [34]. Figure 4 shows that PCSK9 is lower upon Nar treatment with respect to the control, suggesting that this polyphenol downregulates LDLR degradation.
Because Nar modifies the protein network of cholesterol metabolism maintenance, we investigated the putative ERα involvement in these changes. Thus, the ERα pure antagonist ICI 182,780 was administered to HepG2 cells 15 min before Nar treatment and, subsequently, HMGCR protein content and phosphorylation state, as well as LDLR expression, were analyzed. Figure 5A shows that ICI 182,780 prevents Nar-induced HMGCR changes both at protein and phosphorylation levels; conversely, the ERα inhibition cannot prevent LDLR increase induced by Nar (Figure 5B).
ICI 182,780 is an inhibitor of both ER subtypes; to investigate the specific involvement of ERα, subtype HepG2 cells were treated with Endoxifen (a selective ERα inhibitor) 15 min before Nar stimulation. Results show that, like ICI 182,780 treatment, Endoxifen pretreatment prevents Nar-induced HMGCR modulation (Figure 6A), whereas it was incapable of preventing LDLR changes (Figure 6B), confirming that ERα is the main ER subtype expressed in this cell line [25]. Thus, the following experiments were performed in the presence of ICI 182,780.
Nar-induced AMPK activation was hindered by ICI 182,780 administration (Figure 7A). On the contrary, the ER antagonist did not exert any effect on PP2A reduction mediated by Nar (Figure 7B).
Intriguingly, the Nar effect on nSREBP1 and Insig-1 was independent on ERα (Figure 8A,B), whereas Nar-induced Insig-2 modulation depends on ER activation (Figure 8C).

3. Discussion

Eating habits and metabolic disorders are associated with negative effects on the risk factors for cardiovascular diseases, as they can induce increased cholesterol and triglycerides plasma levels. In the last years, natural food components have attracted considerable interest in treating hypercholesterolemia. In general, plant foods provide support for cardiovascular disease prevention due to their low amount of fats and the presence of bioactive compounds, which may act as cholesterol-lowering agents through different mechanisms. Among these molecules, Nar shows hypolipidemic properties both in vivo and in vitro [8,35,36]. Its potential as a normolipidemic agent have been largely established [9,10,11,12,37,38], and a role of PPARα, PPARγ, and LXRα in Nar-dependent lipid lowering has been also demonstrated [39]. Moreover, docking analysis provided evidence that Nar can bind to the active site of HMGCR and compete with the ligand HMG-CoA, thus competitively inhibiting enzyme activity and reducing cholesterol intracellular synthesis [40]. More recently, another report highlights the direct inhibitory activity of Nar; notably, this compound anchors to HMGCR with modes and affinities like those observed for statins [13]. Despite this evidence, it has been postulated that the hypocholesterolemic activity of Nar may be exerted at multiple levels, but the exact molecular mechanisms are still unclear and deserve further investigation [36,41]. Here, we evaluated the Nar-induced modulations of the protein network controlling cholesterol homeostasis. Additionally, since Nar binds to the ERs [14,19,20], the putative implication of ERα in the hypocholesterolemic effects induced by Nar has also been studied. Thus, we chose as experimental model HepG2 cells, which express only ERα subtype [25].
Our results show that Nar administration to HepG2 cell line reduces HMGCR activation state and increases LDLR protein expression, justifying the in vivo lipid-lowering properties exerted by this flavanone [7,37,38,39]. Specifically, Nar affects HMGCR activation state by modulating AMPK and PP2A, the two main proteins implicated in its short-term regulation. Nar also influences HMGCR protein levels, which were decreased upon 24 h treatment. In this context, Nar could govern the long-term regulation of the enzyme not only by suppressing the SREBP-1-mediated transcription, but also probably by enhancing HMGCR degradation through Insig proteins, which were significantly upregulated. Since SREBP-1 isoform is also committed to the regulation of genes involved in fatty acids metabolism [42], the reduction of its transcriptionally active fragment observed in this work further supports the notion that Nar decreases triglyceride content, as already extensively demonstrated [36]. The fact that the level of SREBP-2, the transcription factor devoted to LDLR gene activation, is not modified by Nar administration sustains the hypothesis that the increased level of LDLR could be ascribable to a decreased level of PCSK9, a protein produced by the liver and deeply involved in LDLR degradation [43]. Our results demonstrate that Nar administration can reduce PCSK9 levels, opening a new scenery to the pharmacological intervention on hypercholesterolemia. Indeed, PCSK9 inhibition is considered an attractive target for therapy against hypercholesterolemia. To date, the therapeutic avenues tested to pharmacologically inhibit PCSK9 in humans are mainly focused on gene silencing that targets both PCSK9 intra- and extra-cellular functions and on mimetic peptides and monoclonal antibodies that exclusively target circulating PCSK9 and, therefore, its extracellular function [44]. Thus, Nar-induced PCSK9 reduction may represent a prospective approach to effectively reduce hypercholesterolemia, avoiding the side effects often complained by statin users [4,45] and the high costs of monoclonal antibodies.
To focus our attention on the putative role exerted by ERs in Nar-induced modulation of proteins belonging to cholesterol regulatory network, we used a pharmacological approach by using ICI 182,780, a pure ER antagonist, and Endoxifen, which specifically inhibits ERα. The results demonstrate that, differently from LDLR, Nar-induced HMGCR regulation is dependent on ERs. Interestingly, the regulation of proteins involved in HMGCR phosphorylation, AMPK and PP2A, is dependent and independent on ERs, respectively. Turning the attention on long-term regulation, our results demonstrate that only Nar-dependent Insig-2 increase is influenced by ERs. This feature is supported by previous data establishing a role for Insig-2 as a link between estrogen protective effects and cholesterol homeostasis. In particular, alignment sequence analysis showed that rat Insig-2 gene presents an estrogen response elements-like (ERE-like) within intron 2, suggesting that Nar binding to ERs is able to increase Insig-2 protein level as well as estrogen [22]. To date, the literature data about the useful effects of Nar in the prevention of lipid related pathologies support the concept that the protective activity of this flavanone is mostly due to its high antioxidant and anti-inflammatory effects [36] or through the action of PPARα, PPARγ, and LXRα [39]. However, these effects are obtained at high Nar concentrations ranging from 50 to 200 µM, a concentration difficult to obtain in the plasma after a meal enriched with this flavanone due to the extensive metabolic processes by gut and liver enzymes that transform polyphenol in more soluble compounds. The data collected in the present work, obtained at Nar concentration compatible with its presence in the blood, expand the knowledge about Nar lipid-lowering effects, putting in a new piece in the already available literature. This piece can be added to further effects on different dysfunctions related to metabolism, such as insulin sensitivity [46], artery hypertension [47], and, in general, in metabolic disorders such as obesity and diabetes [48].The hypocholesterolemic effects induced by the flavanone are strictly related to its capability in modulating the protein network of cholesterol homeostasis acting on HMGCR activity and, intriguingly, reducing PCSK9 levels, a pharmacological target to treat hypercholesterolemia that is attracting the efforts of many researchers working in the field. Moreover, we demonstrate for the first time that ERα is inserted in the machinery triggered by Nar to exert its hypocholesterolemic effects, ushering a new vision on diet impact to human health.

4. Materials and Methods

4.1. Materials

All materials used were obtained from commercial sources and of the highest quality available. All materials with no specified source are obtained from Merck (Milano, Italy).

4.2. Cell Culture

HepG2 cells were used as experimental model. Cells were routinely grown in air containing 5% CO2 in RPMI-1640 medium, containing 10% (v/v) fetal calf serum, L-glutamine (2 mM), gentamicin (0.1 mg/mL), and penicillin (100 U/mL). Cells were passaged every 3 days and media changed every 2 days. HepG2 cells were grown to 70% confluence in flasks then stimulated with vehicle (Control, DMSO/PBS, 1/10, v/v), Naringenin (10−7, 10−6, and 10−5 M), for 24 h in presence or in absence of pre-stimulation for 1 h with the ER inhibitor ICI, 182,780 (10−6 M) or the specific ERα inhibitor Endoxifen (10−6 M).

4.3. Western Blot Analysis

Cells were washed twice in phosphate buffer saline (PBS), harvested with trypsin (1%, v/v), and pelleted by centrifugation. Pellets were re-suspended in PBS containing 0.1 M sucrose, 0.05 M KCl, 0.04 M KH2PO4, 30 mM EDTA, pH 7.4, and sonicated. The protein concentration was determined by the Lowry method [49].
Samples, obtained as previously described, were solubilized in 0.25 mM Tris–HCl, (pH 6.8) containing 20% (w/v) SDS, protease inhibitor cocktail (Merck, Milano, Italy), then boiled for 2 min. Solubilized proteins (10 µg) were resolved by SDS–PAGE at 100 V for 1 h and then electrophoretically transferred to nitrocellulose for 80 min at 100 V and 48C. The nitrocellulose was treated with 3% (w/v) bovine serum albumin (BSA) in Tris Buffered Saline (20 mM Trizma base, 137 mM NaCl, 0.1%, v/v, Tween-20, pH 7.6) and then probed over night with the antibodies listed in Table 1. The nitrocellulose was stripped by Restore Western Blot Stripping Buffer (Pierce Chemical, Rockford, IL, USA) for 10 min at room temperature and then probed with anti-α tubulin. Antibody reaction was visualized with chemiolumionescence Western Blotting detection reagent (GE Healthcare, Little Chalfont, UK), as already reported [50].

4.4. Statistical Analysis

Each mean was derived from four different experiments performed in duplicate. The statistical analysis consisted of unpaired t test when two means were compared, or ANOVAs followed by the Tukey’s multiple comparisons test when more than two means were compared. p values under 0.05 were considered statistically significant. All the statistical analyses were performed using GraphPad Prism 7.00 (Graphpad Software Inc., La Jolla, CA, USA) software for Windows.

Author Contributions

Conceptualization, M.M. and V.P.; methodology M.S.; F.A.; M.F.; data curation, M.M.; V.P., M.S.; writing—original draft preparation, V.P.; writing—review and editing, M.M.; V.P.; M.S.; M.F.; F.A. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Excellence Departments, MUR-Italy, Grant/Award Numbers: ARTICOLO 1, COMMI 314-337 LEGGE 232/2016, ARTICOLO 1, awarded to Dept. of Science, University Roma Tre, Rome, Italy for 2018–2022.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. US Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA 2022, 328, 746–753. [Google Scholar] [CrossRef] [PubMed]
  2. Katselou, M.G.; Matralis, A.N.; Kourounakis, A.P. Multi-Target Drug Design Approaches for Multifactorial Diseases: From Neurodegenerative to Cardiovascular Applications. Curr. Med. Chem. 2014, 21, 2743–2787. [Google Scholar] [CrossRef] [PubMed]
  3. Stoekenbroek, R.M.; Kallend, D.; Wijngaard, P.L.; Kastelein, J.J. Inclisiran for the Treatment of Cardiovascular Disease: The ORION Clinical Development Program. Future Cardiol. 2018, 14, 433–442. [Google Scholar] [CrossRef] [PubMed]
  4. Trapani, L.; Segatto, M.; Ascenzi, P.; Pallottini, V. Potential Role of Nonstatin Cholesterol Lowering Agents. IUBMB Life 2011, 63, 964–971. [Google Scholar] [CrossRef]
  5. Trapani, L. New Compounds Able to Control Hepatic Cholesterol Metabolism: Is It Possible to Avoid Statin Treatment in Aged People? WJH 2013, 5, 676. [Google Scholar] [CrossRef]
  6. Joshipura, K.J.; Ascherio, A.; Manson, J.E.; Stampfer, M.J.; Rimm, E.B.; Speizer, F.E.; Hennekens, C.H.; Spiegelman, D.; Willett, W.C. Fruit and Vegetable Intake in Relation to Risk of Ischemic Stroke. JAMA 1999, 282, 1233–1239. [Google Scholar] [CrossRef] [Green Version]
  7. Kurowska, E.M.; Spence, J.D.; Jordan, J.; Wetmore, S.; Freeman, D.J.; Piché, L.A.; Serratore, P. HDL-Cholesterol-Raising Effect of Orange Juice in Subjects with Hypercholesterolemia. Am. J. Clin. Nutr. 2000, 72, 1095–1100. [Google Scholar] [CrossRef] [Green Version]
  8. Wilcox, L.J.; Borradaile, N.M.; de Dreu, L.E.; Huff, M.W. Secretion of Hepatocyte ApoB Is Inhibited by the Flavonoids, Naringenin and Hesperetin, via Reduced Activity and Expression of ACAT2 and MTP. J. Lipid Res. 2001, 42, 725–734. [Google Scholar] [CrossRef]
  9. Kurowska, E.M.; Manthey, J.A.; Casaschi, A.; Theriault, A.G. Modulation of HepG2 Cell Net Apolipoprotein B Secretion by the Citrus Polymethoxyflavone, Tangeretin. Lipids 2004, 39, 143–151. [Google Scholar] [CrossRef]
  10. Borradaile, N.M.; de Dreu, L.E.; Barrett, P.H.R.; Huff, M.W. Inhibition of Hepatocyte ApoB Secretion by Naringenin: Enhanced Rapid Intracellular Degradation Independent of Reduced Microsomal Cholesteryl Esters. J. Lipid Res. 2002, 43, 1544–1554. [Google Scholar] [CrossRef]
  11. Borradaile, N.M.; de Dreu, L.E.; Barrett, P.H.R.; Behrsin, C.D.; Huff, M.W. Hepatocyte ApoB-Containing Lipoprotein Secretion Is Decreased by the Grapefruit Flavonoid, Naringenin, via Inhibition of MTP-Mediated Microsomal Triglyceride Accumulation. Biochemistry 2003, 42, 1283–1291. [Google Scholar] [CrossRef] [PubMed]
  12. Huong, D.T.T.; Takahashi, Y.; Ide, T. Activity and MRNA Levels of Enzymes Involved in Hepatic Fatty Acid Oxidation in Mice Fed Citrus Flavonoids. Nutrition 2006, 22, 546–552. [Google Scholar] [CrossRef] [PubMed]
  13. Grande, F.; Occhiuzzi, M.A.; Perri, M.R.; Ioele, G.; Rizzuti, B.; Statti, G.; Garofalo, A. Polyphenols from Citrus Tacle® Extract Endowed with HMGCR Inhibitory Activity: An Antihypercholesterolemia Natural Remedy. Molecules 2021, 26, 5718. [Google Scholar] [CrossRef] [PubMed]
  14. Galluzzo, P.; Ascenzi, P.; Bulzomi, P.; Marino, M. The Nutritional Flavanone Naringenin Triggers Antiestrogenic Effects by Regulating Estrogen Receptor α-Palmitoylation. Endocrinology 2008, 149, 2567–2575. [Google Scholar] [CrossRef] [Green Version]
  15. Iorga, A.; Cunningham, C.M.; Moazeni, S.; Ruffenach, G.; Umar, S.; Eghbali, M. The Protective Role of Estrogen and Estrogen Receptors in Cardiovascular Disease and the Controversial Use of Estrogen Therapy. Biol. Sex Differ. 2017, 8, 33. [Google Scholar] [CrossRef] [Green Version]
  16. Billon-Galés, A.; Fontaine, C.; Douin-Echinard, V.; Delpy, L.; Berges, H.; Calippe, B.; Lenfant, F.; Laurell, H.; Guéry, J.-C.; Gourdy, P.; et al. Endothelial Estrogen Receptor-α Plays a Crucial Role in the Atheroprotective Action of 17β-Estradiol in Low-Density Lipoprotein Receptor–Deficient Mice. Circulation 2009, 120, 2567–2576. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Ortmann, J.; Veit, M.; Zingg, S.; Di Santo, S.; Traupe, T.; Yang, Z.; Völzmann, J.; Dubey, R.K.; Christen, S.; Baumgartner, I. Estrogen Receptor-α But Not -β or GPER Inhibits High Glucose-Induced Human VSMC Proliferation: Potential Role of ROS and ERK. J. Clin. Endocrinol. Metab. 2011, 96, 220–228. [Google Scholar] [CrossRef] [Green Version]
  18. Simoncini, T.; Genazzani, A.R.; Liao, J.K. Nongenomic Mechanisms of Endothelial Nitric Oxide Synthase Activation by the Selective Estrogen Receptor Modulator Raloxifene. Circulation 2002, 105, 1368–1373. [Google Scholar] [CrossRef] [Green Version]
  19. Totta, P.; Acconcia, F.; Leone, S.; Cardillo, I.; Marino, M. Mechanisms of Naringenin-Induced Apoptotic Cascade in Cancer Cells: Involvement of Estrogen Receptor α and β Signalling. IUBMB Life 2004, 56, 491–499. [Google Scholar] [CrossRef]
  20. Pellegrini, M.; Pallottini, V.; Marin, R.; Marino, M. Role of the Sex Hormone Estrogen in the Prevention of Lipid Disorder. Curr. Med. Chem. 2014, 21, 2734–2742. [Google Scholar] [CrossRef]
  21. Barros, R.P.A.; Gustafsson, J.-Å. Estrogen Receptors and the Metabolic Network. Cell Metab. 2011, 14, 289–299. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. De Marinis, E.; Martini, C.; Trentalance, A.; Pallottini, V. Sex Differences in Hepatic Regulation of Cholesterol Homeostasis. J. Endocrinol. 2008, 198, 635–643. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Pallottini, V.; Bulzomi, P.; Galluzzo, P.; Martini, C.; Marino, M. Estrogen Regulation of Adipose Tissue Functions: Involvement of Estrogen Receptor Isoforms. Infect. Disord.-Drug Targets 2008, 8, 52–60. [Google Scholar] [CrossRef] [PubMed]
  24. Marino, M.; Acconcia, F.; Trentalance, A. Biphasic Estradiol-Induced AKT Phosphorylation Is Modulated by PTEN via MAP Kinase in HepG2 Cells. MBoC 2003, 14, 2583–2591. [Google Scholar] [CrossRef] [PubMed]
  25. Fiocchetti, M.; Nuzzo, M.T.; Totta, P.; Acconcia, F.; Ascenzi, P.; Marino, M. Neuroglobin, a pro-Survival Player in Estrogen Receptor α-Positive Cancer Cells. Cell Death Dis. 2014, 5, e1449. [Google Scholar] [CrossRef] [Green Version]
  26. Lucero, D.; Dikilitas, O.; Mendelson, M.M.; Aligabi, Z.; Islam, P.; Neufeld, E.B.; Bansal, A.T.; Freeman, L.A.; Vaisman, B.; Tang, J.; et al. Transgelin: A New Gene Involved in LDL Endocytosis Identified by a Genome-Wide CRISPR-Cas9 Screen. J. Lipid Res. 2022, 63, 100160. [Google Scholar] [CrossRef]
  27. Huang, P.-P.; Zhu, W.-Q.; Xiao, J.-M.; Zhang, Y.-Q.; Li, R.; Yang, Y.; Shen, L.; Luo, F.; Dai, W.; Lian, P.-A.; et al. Alterations in Sorting and Secretion of Hepatic ApoA5 Induce Hypertriglyceridemia Due to Short-Term Use of Olanzapine. Front. Pharmacol. 2022, 13, 935362. [Google Scholar] [CrossRef]
  28. Goldstein, J.L.; Brown, M.S. Regulation of the Mevalonate Pathway. Nature 1990, 343, 425–430. [Google Scholar] [CrossRef]
  29. Towler, M.C.; Hardie, D.G. AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling. Circ. Res. 2007, 100, 328–341. [Google Scholar] [CrossRef]
  30. Segatto, M.; Di Giovanni, A.; Marino, M.; Pallottini, V. Analysis of the Protein Network of Cholesterol Homeostasis in Different Brain Regions: An Age and Sex Dependent Perspective. J. Cell. Physiol. 2013, 228, 1561–1567. [Google Scholar] [CrossRef]
  31. Espenshade, P.J.; Hughes, A.L. Regulation of Sterol Synthesis in Eukaryotes. Annu. Rev. Genet. 2007, 41, 401–427. [Google Scholar] [CrossRef] [PubMed]
  32. Brown, M.S.; Goldstein, J.L. The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor. Cell 1997, 89, 331–340. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Sever, N.; Yang, T.; Brown, M.S.; Goldstein, J.L.; DeBose-Boyd, R.A. Accelerated Degradation of HMG CoA Reductase Mediated by Binding of Insig-1 to Its Sterol-Sensing Domain. Mol. Cell 2003, 11, 25–33. [Google Scholar] [CrossRef]
  34. Peterson, A.S.; Fong, L.G.; Young, S.G. PCSK9 Function and Physiology. J. Lipid Res. 2008, 49, 1595–1599. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Pereira-Caro, G.; Borges, G.; van der Hooft, J.; Clifford, M.N.; Del Rio, D.; Lean, M.E.J.; Roberts, S.A.; Kellerhals, M.B.; Crozier, A. Orange Juice (Poly)Phenols Are Highly Bioavailable in Humans. Am. J. Clin. Nutr. 2014, 100, 1378–1384. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Orhan, I.E.; Nabavi, S.F.; Daglia, M.; Tenore, G.C.; Mansouri, K.; Nabavi, S.M. Naringenin and Atherosclerosis: A Review of Literature. Curr Pharm Biotechnol 2015, 16, 245–251. [Google Scholar] [CrossRef]
  37. Jung, H.A.; Jung, M.J.; Kim, J.Y.; Chung, H.Y.; Choi, J.S. Inhibitory Activity of Flavonoids from Prunus Davidiana and Other Flavonoids on Total ROS and Hydroxyl Radical Generation. Arch. Pharmacal Res. 2003, 26, 809–815. [Google Scholar] [CrossRef]
  38. Lee, C.-H.; Jeong, T.-S.; Choi, Y.-K.; Hyun, B.-H.; Oh, G.-T.; Kim, E.-H.; Kim, J.-R.; Han, J.-I.; Bok, S.-H. Anti-Atherogenic Effect of Citrus Flavonoids, Naringin and Naringenin, Associated with Hepatic ACAT and Aortic VCAM-1 and MCP-1 in High Cholesterol-Fed Rabbits. Biochem. Biophys. Res. Commun. 2001, 284, 681–688. [Google Scholar] [CrossRef]
  39. Kim, S.-Y.; Kim, H.-J.; Lee, M.-K.; Jeon, S.-M.; Do, G.-M.; Kwon, E.-Y.; Cho, Y.-Y.; Kim, D.-J.; Jeong, K.-S.; Park, Y.B.; et al. Naringin Time-Dependently Lowers Hepatic Cholesterol Biosynthesis and Plasma Cholesterol in Rats Fed High-Fat and High-Cholesterol Diet. J. Med. Food 2006, 9, 582–586. [Google Scholar] [CrossRef]
  40. Goldwasser, J.; Cohen, P.Y.; Yang, E.; Balaguer, P.; Yarmush, M.L.; Nahmias, Y. Transcriptional Regulation of Human and Rat Hepatic Lipid Metabolism by the Grapefruit Flavonoid Naringenin: Role of PPARα, PPARγ and LXRα. PLoS ONE 2010, 5, e12399. [Google Scholar] [CrossRef]
  41. Navarro-González, I.; Pérez-Sánchez, H.; Martín-Pozuelo, G.; García-Alonso, J.; Periago, M.J. The Inhibitory Effects of Bioactive Compounds of Tomato Juice Binding to Hepatic HMGCR: In Vivo Study and Molecular Modelling. PLoS ONE 2014, 9, e83968. [Google Scholar] [CrossRef] [PubMed]
  42. Horton, J.D. Sterol Regulatory Element-Binding Proteins: Transcriptional Activators of Lipid Synthesis. Biochem. Soc. Trans. 2002, 30 Pt 6, 1091–1095. [Google Scholar] [CrossRef] [Green Version]
  43. Poirier, S.; Mayer, G. The Biology of PCSK9 from the Endoplasmic Reticulum to Lysosomes: New and Emerging Therapeutics to Control Low-Density Lipoprotein Cholesterol. Drug Des. Dev. Ther. 2013, 7, 1135–1148. [Google Scholar] [CrossRef] [Green Version]
  44. Cordero, A.; Olmo, M.R.F.; Quiroga, G.A.C.; Romero-Menor, C.; Fácila, L.; Seijas-Amigo, J.; Murillo, J.R.; Sandin, M.; Rodríguez-Mañero, M.; Mora, M.C.B.; et al. Effect of PCSK9 Inhibitors on Remnant Cholesterol and Lipid Residual Risk: The LIPID-REAL Registry. Eur. J. Clin. Invest. 2022, 52, e13863. [Google Scholar] [CrossRef] [PubMed]
  45. Golomb, B.A.; Dimsdale, J.E.; White, H.L.; Ritchie, J.B.; Criqui, M.H. Reduction in Blood Pressure with Statins: Results from the UCSD Statin Study, a Randomized Trial. Arch. Intern. Med. 2008, 168, 721–727. [Google Scholar] [CrossRef]
  46. Murugesan, N.; Woodard, K.; Ramaraju, R.; Greenway, F.L.; Coulter, A.A.; Rebello, C.J. Naringenin Increases Insulin Sensitivity and Metabolic Rate: A Case Study. J. Med. Food 2020, 23, 343–348. [Google Scholar] [CrossRef]
  47. Liu, H.; Zhao, H.; Che, J.; Yao, W. Naringenin Protects against Hypertension by Regulating Lipid Disorder and Oxidative Stress in a Rat Model. Kidney Blood Press. Res. 2022, 47, 423–432. [Google Scholar] [CrossRef]
  48. Casacchia, T.; Occhiuzzi, M.A.; Grande, F.; Rizzuti, B.; Granieri, M.C.; Rocca, C.; Gattuso, A.; Garofalo, A.; Angelone, T.; Statti, G. A pilot study on the nutraceutical properties of the Citrus hybrid Tacle® as a dietary source of polyphenols for supplementation in metabolic disorders. J. Funct. Foods 2019, 52, 370–381. [Google Scholar] [CrossRef]
  49. Lowry, O.H.; Rosebrough, N.J.; Farr, A.L.; Randall, R.J. Protein Measurement with the Folin Phenol Reagent. J. Biol. Chem. 1951, 193, 265–275. [Google Scholar] [CrossRef]
  50. Pallottini, V.; Martini, C.; Cavallini, G.; Donati, A.; Bergamini, E.; Notarnicola, M.; Caruso, M.G.; Trentalance, A. Modified HMG-CoA Reductase and LDLr Regulation Is Deeply Involved in Age-Related Hypercholesterolemia. J. Cell. Biochem. 2006, 98, 1044–1053. [Google Scholar] [CrossRef]
Ijms 23 15809 g001 550
Figure 1. Naringenin dose-dependent effect on HMGCR and LDLR in HepG2 cells. Panel (A) shows the densitometric analyses (left) and a representative Western blot (right) of total and phosphorylated HMGCR after 24-h treatment with different doses of Nar. Panel (B) shows the densitometric analyses (left) and a representative Western blot (right) of LDLR after 24-h treatment with different doses of Nar. The control of protein loading was done with tubulin. The experiments were performed four times in duplicate. The statistical analysis was performed with ANOVA followed by the Tukey’s multiple comparisons test. * = p < 0.05 vs. C; ** = p < 0.01 vs. C; *** = p < 0.001 vs. C.
Figure 1. Naringenin dose-dependent effect on HMGCR and LDLR in HepG2 cells. Panel (A) shows the densitometric analyses (left) and a representative Western blot (right) of total and phosphorylated HMGCR after 24-h treatment with different doses of Nar. Panel (B) shows the densitometric analyses (left) and a representative Western blot (right) of LDLR after 24-h treatment with different doses of Nar. The control of protein loading was done with tubulin. The experiments were performed four times in duplicate. The statistical analysis was performed with ANOVA followed by the Tukey’s multiple comparisons test. * = p < 0.05 vs. C; ** = p < 0.01 vs. C; *** = p < 0.001 vs. C.
Ijms 23 15809 g001
Ijms 23 15809 g002 550
Figure 2. Naringenin effect on AMPK phosphorylation state and PP2A protein content in HepG2 cells. Cells have been treated for 24 h with 10−6 M Nar. Panel (A) represents, on the left, the densitometric analyses of AMPK phosphorylation state expressed as the ratio between P-AMPK and AMPK protein content and, on the right, a representative Western blot. Panel (B) shows the protein content of the catalytic subunit of PP2A. The control of protein loading was done with tubulin. The experiments were performed four times in duplicate. The statistical analysis was performed with unpaired Student’s t test. ** = p < 0.01 vs. C.
Figure 2. Naringenin effect on AMPK phosphorylation state and PP2A protein content in HepG2 cells. Cells have been treated for 24 h with 10−6 M Nar. Panel (A) represents, on the left, the densitometric analyses of AMPK phosphorylation state expressed as the ratio between P-AMPK and AMPK protein content and, on the right, a representative Western blot. Panel (B) shows the protein content of the catalytic subunit of PP2A. The control of protein loading was done with tubulin. The experiments were performed four times in duplicate. The statistical analysis was performed with unpaired Student’s t test. ** = p < 0.01 vs. C.
Ijms 23 15809 g002
Ijms 23 15809 g003 550
Figure 3. Naringenin effect on SREBPs, Scap, and Insigs protein content in HepG2 cells. HepG2 cells were treated for 24 h with 10−6 M Nar. The panels show, on the left, the densitometric analyses and, on the right, representative Western blots. Panels (A–C) illustrate the protein content of SREBP-1 and -2, Scap, and INsig-1 and -2, respectively. The control of protein loading was done with tubulin. The experiments were performed four times in duplicate. The statistical analysis was performed with unpaired Student’s t test. ** = p < 0.01 vs. C.
Figure 3. Naringenin effect on SREBPs, Scap, and Insigs protein content in HepG2 cells. HepG2 cells were treated for 24 h with 10−6 M Nar. The panels show, on the left, the densitometric analyses and, on the right, representative Western blots. Panels (A–C) illustrate the protein content of SREBP-1 and -2, Scap, and INsig-1 and -2, respectively. The control of protein loading was done with tubulin. The experiments were performed four times in duplicate. The statistical analysis was performed with unpaired Student’s t test. ** = p < 0.01 vs. C.
Ijms 23 15809 g003
Ijms 23 15809 g004 550
Figure 4. Naringenin effect on PCSK9 protein content in HepG2 cells. The figure shows the effects of 10−6 M Nar treatment for 24 h on PCSK9. On the left is illustrated the densitometric analysis, and on the right is a representative Western blot. The control of protein loading was done with tubulin. The experiments were performed four times in duplicate. The statistical analysis was performed with unpaired Student’s t test. ** = p < 0.01 vs. C.
Figure 4. Naringenin effect on PCSK9 protein content in HepG2 cells. The figure shows the effects of 10−6 M Nar treatment for 24 h on PCSK9. On the left is illustrated the densitometric analysis, and on the right is a representative Western blot. The control of protein loading was done with tubulin. The experiments were performed four times in duplicate. The statistical analysis was performed with unpaired Student’s t test. ** = p < 0.01 vs. C.
Ijms 23 15809 g004
Ijms 23 15809 g005 550
Figure 5. Involvement of ERs in Naringenin effects on HMGCR and LDLR in HepG2 cells. Panel (A) shows the densitometric analyses (left) and a representative Western blot (right) of total and phosphorylated HMGCR after 24-h treatment with 10−6 M Nar in presence and in absence of 10−6 M of the ER inhibitor ICI182,780 (ICI). Panel (B) shows the densitometric analyses (left) and a representative Western blot (right) of LDLR treated as already described. The control of protein loading was done with tubulin. The experiments were performed four times in duplicate. The statistical analysis was performed with ANOVAs followed by the Tukey’s multiple comparisons test. * = p < 0.05 vs. C; ** = p < 0.01 vs. C; *** = p < 0.001 vs. C.
Figure 5. Involvement of ERs in Naringenin effects on HMGCR and LDLR in HepG2 cells. Panel (A) shows the densitometric analyses (left) and a representative Western blot (right) of total and phosphorylated HMGCR after 24-h treatment with 10−6 M Nar in presence and in absence of 10−6 M of the ER inhibitor ICI182,780 (ICI). Panel (B) shows the densitometric analyses (left) and a representative Western blot (right) of LDLR treated as already described. The control of protein loading was done with tubulin. The experiments were performed four times in duplicate. The statistical analysis was performed with ANOVAs followed by the Tukey’s multiple comparisons test. * = p < 0.05 vs. C; ** = p < 0.01 vs. C; *** = p < 0.001 vs. C.
Ijms 23 15809 g005
Ijms 23 15809 g006 550
Figure 6. Involvement of ERα in Naringenin effects on HMGCR and LDLR in HepG2 cells. HepG2 cells were treated for 24 h with 10−6 M Nar in presence and in absence of the 10−6 M of the ERα inhibitor Endoxifen (E). Panel (A) shows the densitometric analyses (left) and a representative Western blot (right) of total and phosphorylated. Panel (B) shows the densitometric analyses (left) and a representative Western blot (right) of LDLR. The control of protein loading was done with tubulin. The experiments were performed four times in duplicate. The statistical analysis was performed with ANOVAs followed by the Tukey’s multiple comparisons test. *** = p < 0.001 vs. C.
Figure 6. Involvement of ERα in Naringenin effects on HMGCR and LDLR in HepG2 cells. HepG2 cells were treated for 24 h with 10−6 M Nar in presence and in absence of the 10−6 M of the ERα inhibitor Endoxifen (E). Panel (A) shows the densitometric analyses (left) and a representative Western blot (right) of total and phosphorylated. Panel (B) shows the densitometric analyses (left) and a representative Western blot (right) of LDLR. The control of protein loading was done with tubulin. The experiments were performed four times in duplicate. The statistical analysis was performed with ANOVAs followed by the Tukey’s multiple comparisons test. *** = p < 0.001 vs. C.
Ijms 23 15809 g006
Ijms 23 15809 g007 550
Figure 7. Involvement of ERα in Naringenin effects on AMPK phosphorylation state and PP2A in HepG2 cells. HepG2 cells were treated for 24 h with 10−6 M Nar in presence and in absence of the 10−6 M of the ER inhibitor ICI182,780 (ICI). Panel (A) represents, on the left, the densitometric analyses of AMPK phosphorylation state expressed as the ratio between P-AMPK and AMPK protein content and, on the right, a representative Western blot. Panel (B) shows the protein content of the catalytic subunit of PP2A. The control of protein loading was done with tubulin. The experiments were performed four times in duplicate. The statistical analysis was performed with ANOVAs followed by the Tukey’s multiple comparisons test. * = p < 0.05 vs. C; ** = p < 0.01 vs. C.
Figure 7. Involvement of ERα in Naringenin effects on AMPK phosphorylation state and PP2A in HepG2 cells. HepG2 cells were treated for 24 h with 10−6 M Nar in presence and in absence of the 10−6 M of the ER inhibitor ICI182,780 (ICI). Panel (A) represents, on the left, the densitometric analyses of AMPK phosphorylation state expressed as the ratio between P-AMPK and AMPK protein content and, on the right, a representative Western blot. Panel (B) shows the protein content of the catalytic subunit of PP2A. The control of protein loading was done with tubulin. The experiments were performed four times in duplicate. The statistical analysis was performed with ANOVAs followed by the Tukey’s multiple comparisons test. * = p < 0.05 vs. C; ** = p < 0.01 vs. C.
Ijms 23 15809 g007
Ijms 23 15809 g008 550
Figure 8. Involvement of ERs in Naringenin effects on SREBP-1, Insig-1, and -2 in HepG2 cells. HepG2 cells were treated for 24 h with 10−6 M Nar in presence and in absence of the 10−6 M of the ER inhibitor ICI182,780 (ICI). The panels show, on the left, the densitometric analyses and, on the right, representative Western blots. Panels (A–C) illustrate the protein content of SREBP-1, Insig-1, and -2, respectively. The control of protein loading was done with tubulin. The experiments were performed four times in duplicate. The statistical analysis was performed with ANOVAs followed by the Tukey’s multiple comparisons test. * = p < 0.05 vs. C; ** = p < 0.01 vs. C.
Figure 8. Involvement of ERs in Naringenin effects on SREBP-1, Insig-1, and -2 in HepG2 cells. HepG2 cells were treated for 24 h with 10−6 M Nar in presence and in absence of the 10−6 M of the ER inhibitor ICI182,780 (ICI). The panels show, on the left, the densitometric analyses and, on the right, representative Western blots. Panels (A–C) illustrate the protein content of SREBP-1, Insig-1, and -2, respectively. The control of protein loading was done with tubulin. The experiments were performed four times in duplicate. The statistical analysis was performed with ANOVAs followed by the Tukey’s multiple comparisons test. * = p < 0.05 vs. C; ** = p < 0.01 vs. C.
Ijms 23 15809 g008
Table
Table 1. List of antibodies used for western blotting assay.
Table 1. List of antibodies used for western blotting assay.
Primary AntibodySourcesSecondary AntibodySources
Anti-HMGCRUpstate, Lake Placid, NY, USAGoat anti-rabbitUCS Diagnostic, Rome, Italy
Anti-Insig 1Novus Biologicals, Littleton, CO, USAGoat anti-rabbitUCS Diagnostic, Rome, Italy
Anti-Insig 2Santa Cruz Biotechnology, Santa Cruz, CA, USARabbit anti-goatChemicon International,
Temecula, Canada
Anti-SREBP 1
(N-terminal)		Abcam, Cambridge, UKGoat anti-rabbitUCS Diagnostic, Rome, Italy
Anti-SREBP 2
(N-terminal)		Abcam, Cambridge, UKGoat anti-rabbitUCS Diagnostic, Rome, Italy
Anti LDLRAbcam, Cambridge, UKGoat anti-rabbitUCS Diagnostic, Rome, Italy
Anti PCSK9
(Anti NARC-1)		Santa Cruz Biotechnology, Santa Cruz, CA, USAGoat anti-rabbitUCS Diagnostic, Rome, Italy
Anti-tubulinMP Biomedicals, Solon, OH, USAGoat anti-mouseUCS Diagnostic, Rome, Italy
Anti-AMPKαCell Signaling technology, Boston, MA USAGoat anti-rabbitUCS Diagnostic, Rome, Italy
Anti-P-AMPKαCell Signaling technology, Boston, MA USAGoat anti-rabbitUCS Diagnostic, Rome, Italy
Anti-ScapSanta Cruz Biotechnology,
Santa Cruz, CA, USA		Rabbit anti-goatUCS Diagnostic, Rome, Italy
Anti-PP2ASanta Cruz Biotechnology,
Santa Cruz, CA, USA		Goat anti-rabbitUCS Diagnostic, Rome, Italy
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Pallottini, V.; Segatto, M.; Acconcia, F.; Fiocchetti, M.; Marino, M. Mechanism Underlying Naringenin Hypocholesterolemic Effects: Involvement of Estrogen Receptor α Subtype. Int. J. Mol. Sci. 2022, 23, 15809. https://doi.org/10.3390/ijms232415809

AMA Style

Pallottini V, Segatto M, Acconcia F, Fiocchetti M, Marino M. Mechanism Underlying Naringenin Hypocholesterolemic Effects: Involvement of Estrogen Receptor α Subtype. International Journal of Molecular Sciences. 2022; 23(24):15809. https://doi.org/10.3390/ijms232415809

Chicago/Turabian Style

Pallottini, Valentina, Marco Segatto, Filippo Acconcia, Marco Fiocchetti, and Maria Marino. 2022. "Mechanism Underlying Naringenin Hypocholesterolemic Effects: Involvement of Estrogen Receptor α Subtype" International Journal of Molecular Sciences 23, no. 24: 15809. https://doi.org/10.3390/ijms232415809

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop